Orion
Tracked across 2 events · 12 articles · First seen May 21, 2026 · Last active Jun 05, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Orion announced the first clinical data from its Phase 1/2 TEADES trial for ODM-212, an investigational oral pan-TEAD inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting. The results indicated that ODM-212 was…
Impact: Orion announced positive initial Phase 1 results for its investigational drug ODM-212, which could lead to further development and potential market success in oncology.
May 21, 2026 · 6 articles
Business
BlackRock, Inc. disclosed two changes in its shareholding of Orion. On May 29, 2026, BlackRock, Inc.'s total ownership, including direct, indirect, and financial instruments, decreased below 5% of Orion's total shares. Subsequently, on June 4,…
Impact: Orion is the issuer of the shares whose ownership threshold was crossed by BlackRock, Inc. The event details changes in BlackRock, Inc.'s stake in Orion.
Jun 01, 2026 · 6 articles
100
Orion announced clinical dataOrion Pharma Presents...
90
Orion developed ODM-212Orion Pharma Presents...
90
BlackRock decreased shareholding OrionBlackRock crosses Orion...
NEWSDESK
Track Orion live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard